Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Breast04
jRCT2031230723Phase 3Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of datopotamab deruxtecan, durvalumab and pembrolizumab in breast cancer and triple-negative breast cancer (TNBC) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Event-free survival. Started Apr 2024; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on jRCT2031230723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230723.